洁特生物
(688026)
| 流通市值：22.80亿 | | | 总市值：22.81亿 |
| 流通股本：1.40亿 | | | 总股本：1.40亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 107,856,760.78 | 563,976,836.75 | 398,180,432.24 | 268,140,905.35 |
| 营业收入 | 107,856,760.78 | 563,976,836.75 | 398,180,432.24 | 268,140,905.35 |
| 二、营业总成本 | 113,800,338.52 | 485,139,596.82 | 340,567,157.86 | 220,599,611.29 |
| 营业成本 | 70,783,573.11 | 330,528,373.98 | 230,250,909.34 | 153,997,703.2 |
| 税金及附加 | 1,168,554.78 | 11,003,693.74 | 9,228,595.79 | 3,979,869.31 |
| 销售费用 | 9,711,276.48 | 37,719,271.77 | 25,741,151.77 | 16,074,445.66 |
| 管理费用 | 13,486,026.43 | 54,231,251.67 | 36,589,353.62 | 23,849,243.8 |
| 研发费用 | 7,077,500.06 | 29,122,819.08 | 21,096,099.18 | 13,311,672.7 |
| 财务费用 | 11,573,407.66 | 22,534,186.58 | 17,661,048.16 | 9,386,676.62 |
| 其中:利息费用 | 7,384,587.49 | 28,252,128.42 | 21,084,119.7 | 13,980,873.68 |
| 其中:利息收入 | 730,655.7 | 8,137,560.16 | 1,754,847.46 | 1,606,906.12 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | 238,219.18 | - | 732,534.53 |
| 加:投资收益 | 519,336.71 | 2,181,291.36 | 1,921,204.37 | 1,112,409.37 |
| 资产处置收益 | 11,504.42 | -801,080.79 | -238,323.9 | - |
| 资产减值损失(新) | - | -26,572,760.61 | 283,825.69 | 438,825.26 |
| 信用减值损失(新) | 1,334,193.27 | 920,033.54 | 1,667,047.25 | 378,993.48 |
| 其他收益 | 1,157,351.8 | 7,558,664.92 | 4,668,644.59 | 3,060,799.59 |
| 四、营业利润 | -2,921,191.54 | 62,361,607.53 | 65,915,672.38 | 53,264,856.29 |
| 加:营业外收入 | 34,866.91 | 165,982.73 | 149,698.05 | 134,396.48 |
| 减:营业外支出 | 12,947.8 | 1,593,534.01 | 230,139.02 | 58,774.33 |
| 五、利润总额 | -2,899,272.43 | 60,934,056.25 | 65,835,231.41 | 53,340,478.44 |
| 减:所得税费用 | 937,064.96 | 11,839,445.7 | 7,209,481.87 | 5,760,366.87 |
| 六、净利润 | -3,836,337.39 | 49,094,610.55 | 58,625,749.54 | 47,580,111.57 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -3,836,337.39 | 49,094,610.55 | 58,625,749.54 | 47,580,111.57 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -4,223,181.24 | 48,236,305.48 | 57,291,336.8 | 46,338,648.8 |
| 少数股东损益 | 386,843.85 | 858,305.07 | 1,334,412.74 | 1,241,462.77 |
| 扣除非经常损益后的净利润 | -5,396,440.31 | 36,460,806.57 | 53,163,217.03 | 42,916,326.59 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.03 | 0.35 | 0.42 | 0.34 |
| (二)稀释每股收益 | -0.03 | 0.35 | 0.42 | 0.34 |
| 八、其他综合收益 | -89,482.93 | 301,690.5 | 95,203.13 | 147,760.46 |
| 归属于母公司股东的其他综合收益 | -89,482.93 | 301,690.5 | 95,203.13 | 147,760.46 |
| 九、综合收益总额 | -3,925,820.32 | 49,396,301.05 | 58,720,952.67 | 47,727,872.03 |
| 归属于母公司股东的综合收益总额 | -4,312,664.17 | 48,537,995.98 | 57,386,539.93 | 46,486,409.26 |
| 归属于少数股东的综合收益总额 | 386,843.85 | 858,305.07 | 1,334,412.74 | 1,241,462.77 |
| 公告日期 | 2026-04-30 | 2026-04-30 | 2025-10-31 | 2025-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |